Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
QAR 55.07
QAR 4956.07QAR 55.07
QAR 660.47
60 tablet
Free AirMail shipping Hot
QAR 58.74
QAR 3524.26QAR 58.74
QAR 220.09
30 tablet
Free AirMail shipping Hot
QAR 62.41
QAR 1872.18QAR 62.41
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
QAR 66.08
QAR 5947.32QAR 66.08
QAR 330.05
60 tablet
Free AirMail shipping Hot
QAR 67.92
QAR 4074.96QAR 67.92
QAR 109.96
30 tablet
Free AirMail shipping Hot
QAR 69.75
QAR 2092.46QAR 69.75
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
QAR 78.93
QAR 7103.78QAR 78.93
QAR 330.05
60 tablet
Free AirMail shipping Hot
QAR 80.77
QAR 4845.93QAR 80.77
QAR 109.96
30 tablet
Free AirMail shipping Hot
QAR 82.60
QAR 2477.94QAR 82.60
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.